What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Enzyme
His main research concerns Internal medicine, Cardiology, Endocrinology, Myocardial infarction and Heart failure.
Masatsugu Hori combines subjects such as Diabetes mellitus and Anesthesia with his study of Internal medicine.
Masatsugu Hori has researched Endocrinology in several fields, including Cell culture and Cell biology.
His research in Cell biology intersects with topics in Semaphorin and Small interfering RNA.
Masatsugu Hori studied Myocardial infarction and Angioplasty that intersect with Angioscopy.
His Hazard ratio research includes themes of Stroke and Atrial fibrillation.
His most cited work include:
- The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. (1130 citations)
- Clinical Implications of the ‘No Reflow’ Phenomenon A Predictor of Complications and Left Ventricular Remodeling in Reperfused Anterior Wall Myocardial Infarction (940 citations)
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease (914 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Cardiology, Endocrinology, Myocardial infarction and Heart failure.
Internal medicine and Diabetes mellitus are frequently intertwined in his study.
Masatsugu Hori interconnects Anesthesia and Adenosine in the investigation of issues within Cardiology.
His study in Muscle hypertrophy and Insulin are all subfields of Endocrinology.
His research links Hazard ratio with Myocardial infarction.
Masatsugu Hori specializes in Heart failure, namely Diastolic heart failure.
He most often published in these fields:
- Internal medicine (66.27%)
- Cardiology (42.18%)
- Endocrinology (22.57%)
What were the highlights of his more recent work (between 2006-2021)?
- Internal medicine (66.27%)
- Cardiology (42.18%)
- Heart failure (14.88%)
In recent papers he was focusing on the following fields of study:
Masatsugu Hori mainly focuses on Internal medicine, Cardiology, Heart failure, Myocardial infarction and Endocrinology.
His study in Hazard ratio, Atrial fibrillation, Warfarin, Diastolic heart failure and Confidence interval falls within the category of Internal medicine.
Many of his research projects under Cardiology are closely connected to In patient with In patient, tying the diverse disciplines of science together.
His Heart failure study incorporates themes from Heart disease and Diastole.
His studies deal with areas such as Coronary artery disease, Lower risk and Mortality rate as well as Myocardial infarction.
His work on Apoptosis expands to the thematically related Endocrinology.
Between 2006 and 2021, his most popular works were:
- The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. (1130 citations)
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease (914 citations)
- Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. (422 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Enzyme
The scientist’s investigation covers issues in Internal medicine, Cardiology, Heart failure, Endocrinology and Hazard ratio.
His study in Myocardial infarction, Stroke, Rivaroxaban, Atrial fibrillation and Randomized controlled trial falls under the purview of Internal medicine.
His research investigates the connection between Myocardial infarction and topics such as Lower risk that intersect with issues in Survival rate.
His work carried out in the field of Cardiology brings together such families of science as Prospective cohort study, Asymptomatic and Surgery.
His Heart failure research incorporates elements of Myocyte, Heart disease and Diastole.
His research in Endocrinology tackles topics such as Cell biology which are related to areas like Autophagy and Semaphorin.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
